Strategies to Reduce Acute Kidney Injury in Angioplasty

The title of this article leads us to think that we will find a list of things that we can do to reduce kidney injury. However, (unfortunately) sodium bicarbonate showed no benefit over saline and n-acetylcysteine showed no benefit over a placebo for the reduction of kidney damage after coronary angioplasty.

Sub análisis del EXCEL: angioplastia vs cirugía en insuficiencia renal crónicaAmong the protective measures most frequently tested are endovenous sodium bicarbonate and oral n-acetylcysteine, both with conflicting results.

 

The PRESERVE (Prevention of Serious Adverse Events Following Angiography) trial used a 2 × 2 factorial design and randomized 5177 patients with stage III or IV renal insufficiency requiring angiography to 1.26% sodium bicarbonate or 0.9% sodium chloride and n-acetylcysteine or placebo for 5 days. The primary endpoint was a composite of death, need for dialysis, or persistent renal insufficiency at 90 days. Contrast-associated acute kidney injury was a secondary endpoint.


Read also: Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions.


A total of 1161 study patients underwent coronary angioplasty. The mean glomerular filtration rate was 50.7 mL/min/1.73 m2 and 82% of the population had a history of diabetes.

 

The primary endpoint occurred in 2.6% of patients who received sodium bicarbonate vs. 4% of patients who received saline (p = 0.41) and in 3.8% of patients who received n-acetylcysteine vs. 2.8% of patients who received a placebo (p = 0.29). There were no significant differences among groups as regards the incidence of contrast-associated kidney injury.

 

Conclusion

Among patients with chronic kidney disease who underwent angioplasty, there was no benefit of sodium bicarbonate over regular saline or of n-acetylcysteine over placebo for the prevention of contrast-associated kidney injury.

 

Original title: Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention. A Subgroup Analysis of the PRESERVE Trial.

Reference: Santiago Garcia et al. J Am Coll Cardiol Intv 2018;11:2254-61.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe aortic stenosis (AS) and therefore the improvement...

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...